NEW YORK (GenomeWeb) – Investigators shared data this week from a small prospective trial of a blood-based method they developed to test patients with human papillomavirus-associated oral cancers for signs of remission or recurrence.

The approach, which was spearheaded by researchers at the University of North Carolina and is being commercialized by startup Naveris, would potentially allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment, and which might be poised to recur.